{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:42:32Z","timestamp":1769024552049,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T00:00:00Z","timestamp":1467158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Influenza virus evolves constantly in an unpredictable fashion, making it necessary to vaccinate people annually for effective prevention and control of influenza. In general, however, during the first wave of an influenza outbreak caused by a newly emerging virus strain, influenza morbidity and mortality have been observed to rise sharply due to the lack of a matching vaccine. This necessitates the exploration of novel intervention approaches, particularly those prophylactic or therapeutic agents that have a broad range of antiviral activities and are also proven to be non-toxic. Here, we reported that stimulation of the innate immune system by intranasal administration of chitosan as a single agent was sufficient to completely protect BALB\/c mice from lethal infection by H7N9 virus, a newly emerged viral strain that is highly pathogenic to humans. Remarkably, animals could still be protected against lethal challenge by H7N9 (10\u00d7LD<jats:sub>50<\/jats:sub>), even ten days after the intranasal chitosan administration. The significantly enhanced infiltration of leukocytes in the bronchoalveolar lavage and elevated levels of proinflammatory cytokines in the bronchia\/lung tissues revealed the potent activation of mucosal immune responses by intranasally delivered chitosan. We also observed that chitosan can protect mice from three other virus strains. The marked breadth and magnitude of protection against diverse viral strains makes chitosan an attractive candidate as a universal anti-influenza agent.<\/jats:p>","DOI":"10.1038\/srep28729","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T10:08:01Z","timestamp":1467194881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model"],"prefix":"10.1038","volume":"6","author":[{"given":"Mei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,29]]},"reference":[{"key":"BFsrep28729_CR1","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1016\/j.vaccine.2007.07.027","volume":"25","author":"F Carrat","year":"2007","unstructured":"Carrat, F. & Flahault, A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25, 6852\u20136862 (2007).","journal-title":"Vaccine"},{"key":"BFsrep28729_CR2","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1038\/srep03058","volume":"3","author":"JC Dortmans","year":"2013","unstructured":"Dortmans, J. C. et al. Adaptation of novel H7N9 influenza A virus to human receptors. Sci Rep 3, 3058 (2013).","journal-title":"Sci Rep"},{"key":"BFsrep28729_CR3","unstructured":"WHO. Human infection with avian influenza A(H7N9) virus \u2013 update. http:\/\/www.who.int\/csr\/don\/2013_08_11\/en\/ (2013) (Date of access: 11\/08\/2013)."},{"key":"BFsrep28729_CR4","doi-asserted-by":"publisher","first-page":"f4752","DOI":"10.1136\/bmj.f4752","volume":"347","author":"X Qi","year":"2013","unstructured":"Qi, X. et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ 347, f4752 (2013).","journal-title":"BMJ"},{"key":"BFsrep28729_CR5","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","volume":"368","author":"R Gao","year":"2013","unstructured":"Gao, R. et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Me 368, 1888\u20131897 (2013).","journal-title":"N Engl J Me"},{"key":"BFsrep28729_CR6","unstructured":"General Administration of Quality Supervision, Inspection and Quarantine of the People\u2019s Republic of China. One more human H7N9 case in China. http:\/\/www.aqsiq.gov.cn\/xxgk_13386\/tsxx\/yqts\/201506\/t20150615_442593.htm (2015) (Date of access: 15\/06\/2015)."},{"key":"BFsrep28729_CR7","unstructured":"General Administration of Quality Supervision, Inspection and Quarantine of the People\u2019s Republic of China.One more human H7N9 case in China. http:\/\/www.aqsiq.gov.cn\/xxgk_13386\/tsxx\/yqts\/201511\/t20151106_453363.htm (2015) (Date of access: 06\/11\/2015)."},{"key":"BFsrep28729_CR8","unstructured":"General Administration of Quality Supervision, Inspection and Quarantine of the People\u2019s Republic of China. One more human H7N9 case in China. http:\/\/www.aqsiq.gov.cn\/xxgk_13386\/tsxx\/yqts\/201512\/t20151204_455629.htm (2015) (Date of access: 04\/12\/2015)."},{"key":"BFsrep28729_CR9","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(13)61125-3","volume":"381","author":"Y Hu","year":"2013","unstructured":"Hu, Y. et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381, 2273\u20132279 (2013).","journal-title":"Lancet"},{"key":"BFsrep28729_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S1471-4914(02)00010-2","volume":"9","author":"S Ludwig","year":"2003","unstructured":"Ludwig, S., Planz, O., Pleschka, S. & Wolff, T. Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol Med 9, 46\u201352 (2003).","journal-title":"Trends Mol Med"},{"key":"BFsrep28729_CR11","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1038\/nm1141","volume":"10","author":"P Palese","year":"2004","unstructured":"Palese, P. Influenza: old and new threats. Nat Med 10, S82\u2013S87 (2004).","journal-title":"Nat Med"},{"key":"BFsrep28729_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0753-3322(00)89026-5","volume":"54","author":"EG Brown","year":"2000","unstructured":"Brown, E. G. Influenza virus genetics. Biomed Pharmacother 54, 196\u2013209 (2000).","journal-title":"Biomed Pharmacother"},{"key":"BFsrep28729_CR13","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa054512","volume":"353","author":"MD de Jong","year":"2005","unstructured":"de Jong, M. D. et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353, 2667\u20132672 (2005).","journal-title":"N Engl J Med"},{"key":"BFsrep28729_CR14","doi-asserted-by":"publisher","first-page":"e00396","DOI":"10.1128\/mBio.00396-13","volume":"4","author":"HL Yen","year":"2013","unstructured":"Yen, H. L. et al. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R\/K viral population. MBio 4, e00396\u201313 (2013).","journal-title":"MBio"},{"key":"BFsrep28729_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/CVI.00156-06","volume":"13","author":"VC Huber","year":"2006","unstructured":"Huber, V. C. et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13, 981\u2013990 (2006).","journal-title":"Clin Vaccine Immunol"},{"key":"BFsrep28729_CR16","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.4049\/jimmunol.159.11.5197","volume":"159","author":"DJ Topham","year":"1997","unstructured":"Topham, D. J., Tripp, R. A. & Doherty, P. C. CD8+T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159, 5197\u20135200 (1997).","journal-title":"J Immunol"},{"key":"BFsrep28729_CR17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.semcancer.2006.07.005","volume":"16","author":"TI Arnon","year":"2006","unstructured":"Arnon, T. I., Markel, G. & Mandelboim, O. Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol 16, 348\u2013358 (2006).","journal-title":"Semin Cancer Biol"},{"key":"BFsrep28729_CR18","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.4049\/jimmunol.167.9.5286","volume":"167","author":"AO Dokun","year":"2001","unstructured":"Dokun, A. O., Chu, D. T., Yang, L., Bendelac, A. S. & Yokoyama, W. M. Analysis of in situ NK cell responses during viral infection. J Immunol 167, 5286\u20135293 (2001).","journal-title":"J Immunol"},{"key":"BFsrep28729_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/ni714","volume":"2","author":"AO Dokun","year":"2001","unstructured":"Dokun, A. O. et al. Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2, 951\u2013956 (2001).","journal-title":"Nat Immunol"},{"key":"BFsrep28729_CR20","first-page":"193","volume":"230","author":"CH Tay","year":"1998","unstructured":"Tay, C. H., Szomolanyi-Tsuda, E. & Welsh, R. M. Control of infections by NK cells, Curr Top Microbiol Immunol 230, 193\u2013220 (1998).","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFsrep28729_CR21","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1128\/JVI.01805-09","volume":"84","author":"EB Norton","year":"2010","unstructured":"Norton, E. B., Clements, J. D., Voss, T. G. & C\u00e1rdenas-Freytag, L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol 84, 2983\u20132895 (2010).","journal-title":"J Virol"},{"key":"BFsrep28729_CR22","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1016\/j.vaccine.2010.09.019","volume":"28","author":"Z Sui","year":"2010","unstructured":"Sui, Z., Chen, Q., Fang, F., Zheng, M. & Chen, Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28, 7690\u20137698 (2010).","journal-title":"Vaccine"},{"key":"BFsrep28729_CR23","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1007\/s00705-010-0621-4","volume":"155","author":"Z Sui","year":"2010","unstructured":"Sui, Z. et al. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Arch Virol 155, 5535\u20135544 (2010).","journal-title":"Arch Virol"},{"key":"BFsrep28729_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.virusres.2004.02.025","volume":"103","author":"C Hannoun","year":"2004","unstructured":"Hannoun, C., Megas, F. & Piercy, J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103, 133\u2013138 (2004).","journal-title":"Virus Res"},{"key":"BFsrep28729_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3201\/eid1204.051020","volume":"12","author":"W Gerhard","year":"2006","unstructured":"Gerhard, W., Mozdzanowska, K. & Zharikova, D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 12, 569\u2013574 (2006).","journal-title":"Emerg Infect Dis"},{"key":"BFsrep28729_CR26","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1016\/j.vaccine.2005.08.012","volume":"24","author":"RJ Drape","year":"2006","unstructured":"Drape, R. J. et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24, 4475\u20134481 (2006).","journal-title":"Vaccine"},{"key":"BFsrep28729_CR27","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1086\/375056","volume":"36","author":"DS Fedson","year":"2003","unstructured":"Fedson, D. S. Pandemic influenza and the global vaccine supply. Clin Infect Dis 36, 1552\u20131561 (2003).","journal-title":"Clin Infect Dis"},{"key":"BFsrep28729_CR28","unstructured":"Centers for Disease Control and Prevention (CDC). Preliminary assessment of the effectiveness of the 2003\u201304 inactivated influenza vaccine-Colorado, December 2003. MMWR Morb Mortal Wkly Rep 53, 8\u201311 (2004)."},{"key":"BFsrep28729_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1086\/323085","volume":"184","author":"J Nordin","year":"2001","unstructured":"Nordin, J. et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York and Oregon: data from 3 health plans. J Infect Dis 184, 665\u2013670 (2001).","journal-title":"J Infect Dis"},{"key":"BFsrep28729_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1099\/vir.0.80368-0","volume":"86","author":"P Puthavathana","year":"2005","unstructured":"Puthavathana, P. et al. Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol 86, 423\u2013433 (2005).","journal-title":"J Gen Virol"},{"key":"BFsrep28729_CR31","doi-asserted-by":"crossref","unstructured":"Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, et al. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med 360, 2605\u20132615 (2009).","DOI":"10.1056\/NEJMoa0903810"},{"key":"BFsrep28729_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1165\/rcmb.2005-0382OC","volume":"35","author":"IK Demedts","year":"2006","unstructured":"Demedts, I. K., Bracke, K. R., Maes, T., Joos, G. F. & Brusselle, G. G. Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am J Respir Cell Mol Biol 35, 387\u2013393 (2006).","journal-title":"Am J Respir Cell Mol Biol"},{"key":"BFsrep28729_CR33","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI44675","volume":"121","author":"B Piet","year":"2011","unstructured":"Piet, B. et al. CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest 121, 2254\u20132263 (2011).","journal-title":"J Clin Invest"},{"key":"BFsrep28729_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bbrc.2007.02.019","volume":"355","author":"MW Beilharz","year":"2007","unstructured":"Beilharz, M. W., Cummins, J. M. & Bennett, A. L. Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem Biophys Res Commun 355, 740\u2013744 (2007).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep28729_CR35","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.vaccine.2008.12.048","volume":"27","author":"YF Lau","year":"2009","unstructured":"Lau, Y. F., Tang, L. H. & Ooi, E. E. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27, 1354\u20131364 (2009).","journal-title":"Vaccine"},{"key":"BFsrep28729_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev.mi.48.100194.002351","volume":"48","author":"M Debono","year":"1994","unstructured":"Debono, M. & Gordee, R. S. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 48, 471\u2013497 (1994).","journal-title":"Annu Rev Microbiol"},{"key":"BFsrep28729_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0966-842X(00)88890-3","volume":"3","author":"NH Georgopapadakou","year":"1995","unstructured":"Georgopapadakou, N. H. & Tkacz, J. S. The fungal cell wall as a drug target. Trends Microbiol 3, 98\u2013104 (1995).","journal-title":"Trends Microbiol"},{"key":"BFsrep28729_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1292\/jvms.69.535","volume":"69","author":"TJ Kim","year":"2007","unstructured":"Kim, T. J., Kim. K. H. & Lee. J. I. Stimulation of mucosal and systemic antibody responses against recombinant transferrin-binding protein B of Actinobacillus pleuropneumoniae with chitosan after tracheal administration in piglets. The Journal of veterinary medical science 69, 535\u2013539 (2007).","journal-title":"The Journal of veterinary medical science"},{"key":"BFsrep28729_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature05746","volume":"447","author":"TA Reese","year":"2007","unstructured":"Reese, T. A. et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 447, 92\u201396 (2007).","journal-title":"Nature"},{"key":"BFsrep28729_CR40","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1084\/jem.178.6.2243","volume":"178","author":"AM Cooper","year":"1993","unstructured":"Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178, 2243\u20132247 (1993).","journal-title":"J Exp Med"},{"key":"BFsrep28729_CR41","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/0264-410X(92)90108-V","volume":"10","author":"I Azuma","year":"1992","unstructured":"Azuma, I. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 10, 1000\u20131006 (1992).","journal-title":"Vaccine"},{"key":"BFsrep28729_CR42","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/blood.V90.3.909","volume":"90","author":"BJ Rollins","year":"1997","unstructured":"Rollins, B. J. Chemokines. Blood 90, 909\u2013928 (1997).","journal-title":"Blood"},{"key":"BFsrep28729_CR43","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.4049\/jimmunol.178.4.2448","volume":"178","author":"Y Hashimoto","year":"2007","unstructured":"Hashimoto, Y., Moki, T., Takizawa, T., Shiratsuchi, A. & Nakanishi, Y. Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol 178, 2448\u20132457 (2007).","journal-title":"J Immunol"},{"key":"BFsrep28729_CR44","doi-asserted-by":"publisher","first-page":"e17618","DOI":"10.1371\/journal.pone.0017618","volume":"6","author":"MD Tate","year":"2011","unstructured":"Tate, M. D. et al. The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One 6, e17618 (2011).","journal-title":"PLoS One"},{"key":"BFsrep28729_CR45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1465-9921-9-57","volume":"9","author":"MD Tate","year":"2008","unstructured":"Tate, M. D., Brooks, A. & Reading, P. C. The role of neutrophils in the upper and lower respiratory tract during influenza virus infection of mice. Respir Res 9, 57 (2008).","journal-title":"Respir Res"},{"key":"BFsrep28729_CR46","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.bbrc.2006.03.088","volume":"343","author":"M Qiu","year":"2006","unstructured":"Qiu, M. et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB\/c mice. Biochem Biophys Res Commun 343, 1124\u20131131 (2006).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep28729_CR47","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1089\/dna.2005.24.758","volume":"24","author":"F Zhang","year":"2005","unstructured":"Zhang, F. et al. Maternal immunization with both hemagglutinin- and neuraminidase-expressing DNAs provides an enhanced protection against a lethal influenza virus challenge in infant and adult mice. DNA Cell Biol 24, 758\u2013765 (2005).","journal-title":"DNA Cell Biol"},{"key":"BFsrep28729_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbrc.2005.01.109","volume":"329","author":"Q Zhu","year":"2005","unstructured":"Zhu, Q. et al. Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice. Biochem Biophys Res Commun 329, 87\u201389 (2005).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep28729_CR49","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00705-010-0756-3","volume":"155","author":"L Guo","year":"2010","unstructured":"Guo, L. et al. Protection against multiple influenza A subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol 155, 1765\u20131775 (2010).","journal-title":"Arch Virol"},{"key":"BFsrep28729_CR50","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493\u2013497 (1938).","journal-title":"Am J Hyg"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep28729","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28729.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28729.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:21:35Z","timestamp":1672849295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep28729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFsrep28729"],"URL":"https:\/\/doi.org\/10.1038\/srep28729","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,29]]},"assertion":[{"value":"27 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28729"}}